Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Rationale Some of the behavioral consequences of deficits in N-methyl-D-aspartate (NMDA) glutamate receptor function are thought to arise from the disinhibition of cortical glutamatergic circuitry.Objective This study evaluated whether pretreatment with a drug that reduces glutamatergic activation, the group II metabotropic glutamate receptor (mGluR) agonist, LY354740, reduced the cognitive effects of the NMDA glutamate receptor antagonist, ketamine, in healthy human subjects.Methods Nineteen healthy human subjects completed 3 test days during which LY354740 (matched placebo, 100 mg, 400 mg) was administered under double-blind conditions 4 h prior to the single-blind intravenous administration of saline and 5.7 h prior to ketamine administration (bolus of 0.26 mg/kg over 1 min, infusion of 0.65 mg/kg per hour for 100 min). Thus on each test day each subject received a single dose of LY354740 (or its matched placebo) and both saline and ketamine infusions.Results Ketamine impaired attention, working memory, and delayed recall. It also produced positive and negative symptoms, perceptual changes, and dysphoric mood. LY354740 did not have a significant effect on working memory on the placebo day; however, it produced a significant dose-related improvement in working memory during ketamine infusion.Conclusions These data provide preliminary and suggestive evidence that LY354740 or other group II mGluR agonists might play a role in treating working memory impairment related to deficits in NMDA receptor function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early studies have shown that inhibitors of glutamate release attenuate the ketamine-induced psychotomimetic symptoms [20][21][22][23].”
From The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects (2018) · cites this paper as [21]
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Self-citationPHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS
Conn, P. J., & Pin, J.-P. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.205 · Cited by 3,081
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
(1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
The hopkins verbal learning test: Development of a new memory test with six equivalent forms
Brandt, J. (1991) · Clinical Neuropsychologist · doi:10.1080/13854049108403297 · Cited by 1,317 · cited 5×
“These tests included a continuous performance test of vigilance and distractibility (Gordon 1983), a non-verbal test of working memory (Belger et al. 1998), and the Hopkins Verbal Learning Test (HVLT) (Brandt 1991).”
MethodInfluentialPharmacological agents acting at subtypes of metabotropic glutamate receptors
Schoepp, D. D., Jane, D. E., & Monn, J. A. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00092-1 · Cited by 1,060
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020 · cited 3×
“…of GABAergic interneurons over the activity of principal neurons within limbic and cortical circuitry (Grunze et al. 1996; Yonezawa et al. 1998; Olney et al. 1999; Sharp et al. 2001; Maccaferri and Dingledine 2002), resulting in disinhibition of glutamatergic neurons, i.e. increased glutamate…”
BackgroundThe Positive and Negative Syndrome Scale (PANSS): rationale and standardisation
Kay, S. R., Opler, L. A., & Lindenmayer, J.-P. (1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291514 · Cited by 1,016 · cited 5×
“The positive and negative symptom scale (PANSS) (Kay et al. 1989) was administered at 120, 245, 345, 500, and 530 min following LY354740 administration (the latter two ratings were safety measures used only to document the return to baseline before discharge on each test day; since this occurred in all cases, these da…”
MethodInfluentialReversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Synaptic basis of cortical persistent activity: the importance of NMDA receptors to working memory
Wang, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-21-09587.1999 · Cited by 859 · cited 2×
“1997) and to augment the negative impact of NMDA receptor blockade upon cortical neural network functions (Lisman et al. 1998; Wang 1999; Krystal et al. 2003).”
BackgroundPharmacologic effects of CI‐581, a new dissociative anesthetic, in man
Domino, E. F., Chodoff, P., & Corssen, G. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563279 · Cited by 748
Schoepp, D. D. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29296-x · Cited by 690
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers
Malhotra, A. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680
Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
Newcomer, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00067-0 · Cited by 604
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530 · cited 3×
“…is more likely to stimulate non-NMDA receptors (AMPA, kainate, and metabotropic glutamate receptors (mGluR)) (Moghaddam et al. 1997) and to augment the negative impact of NMDA receptor blockade upon cortical neural network functions (Lisman et al. 1998; Wang 1999; Krystal et al. 2003).”
BackgroundSelf-citationNMDA-dependent modulation of CA1 local circuit inhibition
Grunze, H., Rainnie, D., Hasselmo, M., Barkai, E., Hearn, E., McCarley, R., & Greene, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02034.1996 · Cited by 467 · cited 3×
“A growing literature suggests that a component of the cognitive and behavioral effects of subanesthetic doses of NMDA receptor antagonists arises from their preferential inhibition of GABAergic interneurons over the activity of principal neurons within limbic and cortical circuitry (Grunze et al. 1996; Yonezawa et al.…”
BackgroundA role for NMDA-receptor channels in working memory
Lisman, J. E., Fellous, J.-M., & Wang, X.-J. (1998) · Nature Neuroscience · doi:10.1038/1086 · Cited by 438
Ketamine activates psychosis and alters limbic blood flow in schizophrenia
Lahti, A. C., Holcomb, H. H., Medoff, D. R., & Tamminga, C. A. (1995) · NeuroReport · doi:10.1097/00001756-199504190-00011 · Cited by 434
Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors.
Oye, I., Paulsen, O., & Maurset, A. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11430-4 · Cited by 429
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426 · cited 3×
“…to evaluate the contribution of NMDA glutamate receptors to executive cognitive functions, memory, and psychosis (Krystal et al. 1994, 1998b, 1999b), including a study that evaluated the interactive effects of ketamine and another glutamate releaseinhibiting drug, lamotrigine (Anand et al. 2000).”
BackgroundSelf-citationBell, M. D., Lysaker, P. H., Beam-Goulet, J. L., Milstein, R. M., & Lindenmayer, J.-P. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90075-2 · Cited by 422
Nusser, Z., Mulvihill, E., Streit, P., & Somogyi, P. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90421-9 · Cited by 415
Vollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00042-9 · Cited by 413
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.805 · Cited by 392 · cited 2×
“…of subanesthetic doses of NMDA receptor antagonists elevate resting regional cortical blood flow and metabolism in humans (Lahti et al. 1995; Breier et al. 1997; Vollenweider et al. 1997), and the human cortical excitatory response to transcranial magnetic stimulation (Di Lazzaro et al.…”
BackgroundSelf-citationHelton, D. R., Tizzano, J. P., Monn, J. A., Schoepp, D. D., & Kallman, M. J. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37253-2 · Cited by 279
Cartmell, J., Monn, J. A., & Schoepp, D. D. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35084-0 · Cited by 269
Ketamine Increases Human Motor Cortex Excitability to Transcranial Magnetic Stimulation
Lazzaro, V. D., Oliviero, A., Profice, P., Pennisi, M. A., Pilato, F., Zito, G., Dileone, M., Nicoletti, R., Pasqualetti, P., & Tonali, P. A. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2002.030486 · Cited by 254
NMDA receptor regulation of memory and behavior in humans
Newcomer, J. W., & Krystal, J. H. (2001) · Hippocampus · doi:10.1002/hipo.1069 · Cited by 241
Self-citationKrystal, J. (1999) · Harvard Review of Psychiatry · doi:10.1093/hrp/7.3.125 · Cited by 232
Self-citationImaging subcortical auditory activity in humans
Guimarães, A. R., Melcher, J. R., Talavage, T. M., Baker, J. R., Ledden, P. J., Rosen, B. R., Kiang, N. Y.-S., Fullerton, B. C., & Weisskoff, R. M. (1998) · Human Brain Mapping · doi:10.1002/(sici)1097-0193(1998)6:1<33::aid-hbm3>3.0.co;2-m · Cited by 218
Self-citationLY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress
Schoepp, D. D., Wright, R. A., Levine, L. R., Gaydos, B., & Potter, W. Z. (2003) · Stress · doi:10.1080/1025389031000146773 · Cited by 207
Self-citationBelger, A., Puce, A., Krystal, J. H., Gore, J. C., Goldman-Rakic, P., & McCarthy, G. (1998) · Human Brain Mapping · doi:10.1002/(sici)1097-0193(1998)6:1<14::aid-hbm2>3.0.co;2-o · Cited by 203
Self-citationInteractive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
Krystal, J. H., Karper, L. P., Bennett, A., D'Souza, D. C., Abi-Dargham, A., Morrissey, K., Abi-Saab, D., Bremner, J. D., Bowers Jr., M. B., Suckow, R. F., et al. (1998) · Psychopharmacology · doi:10.1007/s002130050503 · Cited by 184
Self-citationSharp, F. R., Tomitaka, M., Bernaudin, M., & Tomitaka, S. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01817-8 · Cited by 158
Yonezawa, Y., Kuroki, T., Kawahara, T., Tashiro, N., & Uchimura, H. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01435-0 · Cited by 142
Maccaferri, G., & Dingledine, R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05462.2002 · Cited by 121
The Arrangement of Glutamate Receptors in Excitatory Synapses
TAKUMI, Y., MATSUBARA, A., RINVIK, E., & OTTERSEN, O. P. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb11316.x · Cited by 108
Spooren, W. P. J. M., Gasparini, F., van der Putten, H., Koller, M., Nakanishi, S., & Kuhn, R. R. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00269-7 · Cited by 94
Nestor, P. G., Faux, S. F., McCarley, R. W., Shenton, M. E., & Sands, S. F. (1990) · Schizophrenia Research · doi:10.1016/0920-9964(90)90018-3 · Cited by 81
Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists
Krystal, J. H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00102-5 · Cited by 78
Self-citationLamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice
Brody, S. A., Geyer, M. A., & Large, C. H. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1421-2 · Cited by 75
Krupitsky, E. M., Burakov, A. M., Romanova, T. N., Grinenko, N. I., Grinenko, A. Y., Fletcher, J., Petrakis, I. L., & Krystal, J. H. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00346-3 · Cited by 61
Neuroleptics improve sustained attention in schizophrenia. A study using signal detection theory.
Nestor, P. G., Faux, S. F., McCarley, R. W., Sands, S. F., Horvath, T., & Peterson, A. (1991) · PubMed · Cited by 60
Research works printed but not linked: 4
- Farber NB, Newcomer JW, Olney JW (1999) Lamotrigine prevents NMDA antagonist neurotoxicity. Schizophr Res 36:308
- Gordon M (1983) Gordon diagnostic systems. Gordon Systems, DeWitt
- Krystal JH, Belger A, Kirino E, Gore J, McCarthy G (1998a) Ketamine effects on the cortical processing of novelty in humans assessed with fMRI. Soc Neurosci Abstr 24:#104.7
- Spitzer RL, Williams JBW, Gibbon M, First MB (1990) Structured clinical interview for DSM-III-R-non-patient edition (SCID-NP, version 1.0 with supplement for DSM-IV). American Psychiatric Press, Washington D.C.
Cited by
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Self-citationJavitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Schobel, S. A., Chaudhury, N. H., Khan, U. A., Paniagua, B., Styner, M. A., Asllani, I., Inbar, B. P., Corcoran, C. M., Lieberman, J. A., Moore, H., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.011 · Cited by 549
Metadata
- Authors
- Krystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., & Breier, A.
- Affiliations
- VA Connecticut Healthcare System (US)
- Yale University (US)
- Eli Lilly (United States) (US)
- Corresponding author
- Krystal, John H.
- Venue
- Psychopharmacology
- Published
- 2004-08-10
- Volume
- 179
- Issue
- 1
- Pages
- 303-309
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2072471087
- Cited by
- 272
- References
- 42
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 4 · 2023: 12 · 2022: 7 · 2021: 7 · 2020: 5 · 2019: 8 · 2018: 8 · 2017: 9 · 2016: 11 · 2015: 16 · 2014: 8 · 2013: 18 · 2012: 17
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- National Institutes of Health (5k05aa014906-03)
- National Institute on Alcohol Abuse and Alcoholism (KO5 AA014906-01)
- National Institute of Mental Health (5P50 MH44866-12, P50MH044866)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- ketamine, LY354740, NMDA receptor antagonism, working memory, cognitive impairment, attention, delayed recall, positive and negative symptoms
- MeSH terms
- Adult, Bridged Bicyclo Compounds, Double-Blind Method, Female, Humans, Ketamine, Male, Memory, Single-Blind Method, Receptors, N-Methyl-D-Aspartate, Receptors, Metabotropic Glutamate, Excitatory Amino Acid Agonists, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.